LT2889033T - Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis - Google Patents

Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis

Info

Publication number: LT2889033T
Authority: LT; Lithuania
Prior art keywords: quinuclidin; schizophrenia; carboxamide; thiophene; benzo
Prior art date: 2008-11-19

Application number

LTEP15151165.6T

Other languages

English (en)

Inventor

Gerhard Koenig

Richard Chesworth

Gideon Shapiro

Original Assignee

Forum Pharmaceuticals Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-19

Filing date

2009-11-19

Publication date

2018-07-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41786120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2889033(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-11-19 Application filed by Forum Pharmaceuticals Inc. filed Critical Forum Pharmaceuticals Inc.

2018-07-10 Publication of LT2889033T publication Critical patent/LT2889033T/lt

Links

SSRDSYXGYPJKRR-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC(C=CC=C2Cl)=C2S1 SSRDSYXGYPJKRR-ZDUSSCGKSA-N 0.000 title 1
150000003839 salts Chemical class 0.000 title 1
201000000980 schizophrenia Diseases 0.000 title 1
208000024891 symptom Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LTEP15151165.6T 2008-11-19 2009-11-19 Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis LT2889033T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11610608P	2008-11-19	2008-11-19

Publications (1)

Publication Number	Publication Date
LT2889033T true LT2889033T (lt)	2018-07-10

Family

ID=41786120

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP15151165.6T LT2889033T (lt)	2008-11-19	2009-11-19	Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis

Country Status (34)

Country	Link
US (6)	US8642638B2 (lt)
EP (4)	EP2355822B1 (lt)
JP (6)	JP5272080B2 (lt)
KR (3)	KR20180011888A (lt)
CN (3)	CN105687191A (lt)
AU (1)	AU2009316557B2 (lt)
BR (1)	BRPI0922057A2 (lt)
CA (3)	CA2894860C (lt)
CL (3)	CL2011001178A1 (lt)
CO (1)	CO6400190A2 (lt)
CR (1)	CR20110267A (lt)
CY (3)	CY1113671T1 (lt)
DK (3)	DK2540297T3 (lt)
EC (1)	ECSP11011076A (lt)
ES (3)	ES2396300T3 (lt)
HR (3)	HRP20130007T1 (lt)
HU (2)	HUE037938T2 (lt)
IL (5)	IL212921A (lt)
LT (1)	LT2889033T (lt)
MX (1)	MX2011005270A (lt)
MY (2)	MY159826A (lt)
NZ (2)	NZ613291A (lt)
PE (1)	PE20110711A1 (lt)
PH (2)	PH12014501629B1 (lt)
PL (3)	PL2889033T3 (lt)
PT (3)	PT2355822E (lt)
RS (1)	RS52583B (lt)
RU (3)	RU2532327C2 (lt)
SG (1)	SG10201504102QA (lt)
SI (3)	SI2540297T1 (lt)
SM (3)	SMT201800308T1 (lt)
TR (1)	TR201807944T4 (lt)
WO (1)	WO2010059844A1 (lt)
ZA (1)	ZA201104044B (lt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
CA2894860C (en)	2008-11-19	2018-11-06	Gerhard Koenig	Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
MX357676B (es)	2010-05-17	2018-07-18	Forum Pharmaceuticals Inc	Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado.
EP2640378A4 (en) *	2010-11-18	2014-05-21	Envivo Pharmaceuticals Inc	INFLAMMATION TREATMENT WITH CERTAIN NICOTINIC ACID ALPHA-7 RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS
EP2706854A4 (en) *	2011-05-09	2014-12-03	Envivo Pharmaceuticals Inc	TREATMENT OF COGNITIVE DISORDERS BY CERTAIN AGONISTS OF THE ALPHA-7 NICOTINIC RECEPTOR IN COMBINATION WITH NICOTINE
CA2840746A1 (en) *	2011-07-01	2013-01-10	Envivo Pharmaceuticals, Inc.	Methods of treatment of limited cognitive impairment
EP3666272A1 (en) *	2012-05-08	2020-06-17	Forum Pharmaceuticals Inc.	Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit
ES3002659T3 (en)	2017-02-27	2025-03-07	Univ Of Pittsburgh Of The Commonwealthsystem Of Higher Education	Anti-psychotic composition and treatment methods
WO2019060298A1 (en)	2017-09-19	2019-03-28	Neuroenhancement Lab, LLC	METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en)	2017-12-04	2023-08-08	Neuroenhancement Lab, LLC	Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en)	2017-12-31	2025-04-22	NeuroLight, Inc.	Method and apparatus for neuroenhancement to enhance emotional response
US11318277B2 (en)	2017-12-31	2022-05-03	Neuroenhancement Lab, LLC	Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en)	2018-04-20	2022-06-21	Neuroenhancement Lab, LLC	System and method for inducing sleep by transplanting mental states
CN113382683A (zh)	2018-09-14	2021-09-10	纽罗因恒思蒙特实验有限责任公司	改善睡眠的系统和方法

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5122528A (en)	1983-12-22	1992-06-16	Erbamont, Inc.	Analgesic use of benzobicyclic carboxamides
US4605652A (en)	1985-02-04	1986-08-12	A. H. Robins Company, Inc.	Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
EP0385517B1 (en)	1985-03-14	1993-04-14	BEECHAM GROUP plc	Medicaments for the treatment of emesis
HU895334D0 (en)	1986-07-30	1990-01-28	Sandoz Ag	Process for the preparation of nasal pharmaceutical compositions
DE3827253A1 (de)	1987-08-20	1989-03-02	Sandoz Ag	Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE3740984A1 (de)	1987-12-03	1989-06-15	Sandoz Ag	N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung
US5198437A (en)	1987-12-10	1993-03-30	Duphar International Research B.V.	1,7-annelated indolecarboxylic acid esters and amides
US4985420A (en)	1987-12-10	1991-01-15	Duphar International Research B.V.	1,7-annelated indolecarboxylic acid esters and -amides
US4863919A (en)	1988-02-01	1989-09-05	A. H. Robins Company, Incorporated	Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
DE3810552A1 (de)	1988-03-29	1989-10-19	Sandoz Ag	Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
EP0353371A1 (en)	1988-08-04	1990-02-07	Synthelabo	Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
IE62662B1 (en)	1989-01-06	1995-02-22	Elan Corp Plc	Use of nicotine in the treatment of conditions susceptible to said treatment
US5189041A (en)	1990-11-16	1993-02-23	Syntex (U.S.A.) Inc.	Tricyclic 5-ht3 receptor antagonists
US5114947A (en)	1990-12-27	1992-05-19	Erbamont Inc.	Method for alleviating anxiety using benzobicyclic carboxamides
DE4115215A1 (de)	1991-05-10	1992-11-12	Merck Patent Gmbh	Indolderivate
SE9201478D0 (sv)	1992-05-11	1992-05-11	Kabi Pharmacia Ab	Heteroaromatic quinuclidinenes, their use and preparation
US5977144A (en)	1992-08-31	1999-11-02	University Of Florida	Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
PT777671E (pt)	1994-08-24	2000-08-31	Astrazeneca Ab	Compostos espiro-azabiciclicos uteis em terapia
US5703116A (en)	1995-04-18	1997-12-30	Geron Corporation	Telomerase Inhibitors
US5863936A (en)	1995-04-18	1999-01-26	Geron Corporation	Telomerase inhibitors
US5760062A (en)	1995-04-18	1998-06-02	Geron Corporation	Telomerase inhibitors
US5656638A (en)	1995-04-18	1997-08-12	Geron Corporation	Telomerase inhibitors
GB9606736D0 (en)	1996-02-19	1996-06-05	Shire International Licensing	Therapeutic method
FR2756826B1 (fr)	1996-12-05	1999-01-08	Adir	Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2289574C (en)	1997-05-30	2007-04-24	Neurosearch A/S	8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
US7214686B2 (en)	1997-06-30	2007-05-08	Targacept, Inc.	Pharmaceutical compositions and methods for effecting dopamine release
JPH1180027A (ja)	1997-09-12	1999-03-23	Dai Ichi Seiyaku Co Ltd	向知性薬
US6875606B1 (en)	1997-10-23	2005-04-05	The United States Of America As Represented By The Department Of Veterans Affairs	Human α-7 nicotinic receptor promoter
US6277870B1 (en)	1998-05-04	2001-08-21	Astra Ab	Use
WO2000017356A2 (en)	1998-09-18	2000-03-30	The Rockefeller University	Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof
US6953855B2 (en)	1998-12-11	2005-10-11	Targacept, Inc.	3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en)	1998-12-11	2002-08-13	Targacept, Inc.	Pharmaceutical compositions and methods for use
SE9900100D0 (sv)	1999-01-15	1999-01-15	Astra Ab	New compounds
FR2790474B1 (fr)	1999-03-05	2001-04-06	Synthelabo	Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
FR2791678B1 (fr)	1999-03-30	2001-05-04	Synthelabo	Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US6416735B1 (en)	1999-11-08	2002-07-09	Research Triangle Institute	Ligands for α-7 nicotinic acetylcholine receptors based on methyllcaconitine
WO2001040261A1 (en)	1999-12-01	2001-06-07	Ortho-Mcneil Pharmaceutical, Inc.	Method of diagnosing neurodegenerative disease
EP1237923A2 (en)	1999-12-14	2002-09-11	PHARMACIA & UPJOHN COMPANY	Human ion channels
FR2804430B1 (fr)	2000-01-28	2002-03-22	Sanofi Synthelabo	Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en)	2000-05-05	2000-06-28	Novartis Ag	Organic compounds
AU2001252463A1 (en)	2000-06-06	2001-12-17	Pfizer Products Inc.	Thiophene derivatives useful as anticancer agents
TW593223B (en)	2000-06-20	2004-06-21	Merz Pharma Gmbh & Co Kgaa	1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
FR2810664B1 (fr)	2000-06-27	2004-12-24	Adir	Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4616971B2 (ja)	2000-07-18	2011-01-19	田辺三菱製薬株式会社	１−アザビシクロアルカン化合物およびその医薬用途
US20030092613A1 (en)	2000-08-14	2003-05-15	Lee Daniel H. S.	Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
WO2002016356A2 (en)	2000-08-18	2002-02-28	Pharmacia & Upjohn Company	Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
EP1381603A2 (en)	2000-08-18	2004-01-21	PHARMACIA & UPJOHN COMPANY	Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US6492385B2 (en)	2000-08-18	2002-12-10	Pharmacia & Upjohn Company	Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6500840B2 (en)	2000-08-21	2002-12-31	Pharmacia & Upjohn Company	Quinuclidine-substituted heteroaryl moieties for treatment of disease
DE10044905A1 (de)	2000-09-12	2002-03-21	Merck Patent Gmbh	(2-Azabicyclo[2.2.1]hept-7-yl)methanol-Derivate als nikontinische Acetylcholinrezeptor Agonisten
US20020086871A1 (en)	2000-12-29	2002-07-04	O'neill Brian Thomas	Pharmaceutical composition for the treatment of CNS and other disorders
ES2275808T3 (es)	2001-02-06	2007-06-16	Pfizer Products Inc.	Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos.
GB0108337D0 (en)	2001-04-03	2001-05-23	Novartis Ag	Organic compounds
US6569865B2 (en)	2001-06-01	2003-05-27	Astrazeneca Ab	Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AR036040A1 (es)	2001-06-12	2004-08-04	Upjohn Co	Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
BR0212123A (pt)	2001-08-24	2004-07-20	Upjohn Co	7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças
JP2003081978A (ja)	2001-09-10	2003-03-19	Mitsubishi Pharma Corp	スピロ環式化合物およびその医薬用途
EP1425286B1 (en)	2001-09-12	2007-02-28	Pharmacia & Upjohn Company LLC	Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases
EP1432707B1 (en)	2001-10-02	2012-03-28	Pharmacia & Upjohn Company LLC	Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
CA2464194A1 (en)	2001-10-26	2003-05-08	Pharmacia & Upjohn Company	N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists
MXPA04004464A (es)	2001-11-08	2004-08-11	Upjohn Co	Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
US6951868B2 (en)	2001-11-09	2005-10-04	Pfizer Inc.	Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
GB0127008D0 (en)	2001-11-09	2002-01-02	Novartis Ag	Organic compounds
DE10156719A1 (de)	2001-11-19	2003-05-28	Bayer Ag	Heteroarylcarbonsäureamide
FR2832714B1 (fr)	2001-11-23	2004-07-16	Sanofi Synthelabo	Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2832713B1 (fr)	2001-11-23	2004-02-13	Sanofi Synthelabo	Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2832712B1 (fr)	2001-11-23	2004-02-13	Sanofi Synthelabo	Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
AU2002360598B2 (en)	2001-12-14	2008-02-14	Medical College Of Georgia Research Institute, Inc.	Methods and compositions for treatment of central nervous system disorders
DE10162442A1 (de)	2001-12-19	2003-07-03	Bayer Ag	Monocyclische N-Aryl-amide
DE10162375A1 (de)	2001-12-19	2003-07-10	Bayer Ag	Bicyclische N-Aryl-amide
DE10164139A1 (de) *	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
JP2005522456A (ja)	2002-02-15	2005-07-28	ファルマシア・アンド・アップジョン・カンパニー・エルエルシー	Ｃｎｓ関連障害治療のためのアザビシクロ置換ベンゾイルアミドおよびチオアミド
BR0307782A (pt)	2002-02-19	2005-01-04	Upjohn Co	Compostos azabiciclo para o tratamento de doença
US6858613B2 (en)	2002-02-19	2005-02-22	Pfizer Inc.	Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
WO2003072578A1 (en)	2002-02-20	2003-09-04	Pharmacia & Upjohn Company	Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
DE10211415A1 (de)	2002-03-15	2003-09-25	Bayer Ag	Bicyclische N-Biarylamide
DE10211416A1 (de)	2002-03-15	2003-09-25	Bayer Ag	Essig- und Propionsäureamide
US20030236287A1 (en)	2002-05-03	2003-12-25	Piotrowski David W.	Positive allosteric modulators of the nicotinic acetylcholine receptor
AU2003267174A1 (en)	2002-05-09	2003-11-11	Memory Pharmaceuticals Corporation	Qm-7 and qt-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
MXPA05000754A (es)	2002-07-17	2005-04-19	Warner Lambert Co	Combinacion de un inhibidor carboxilico alosterico de la metaloproteinasa de matriz-13 con celecoxib o valdecoxib.
DE10234424A1 (de)	2002-07-29	2004-02-12	Bayer Ag	Benzothiophen-, Benzofuran- und Indolharnstoffe
WO2004014909A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
JP2006503008A (ja)	2002-08-13	2006-01-26	ワーナー−ランバートカンパニーリミティドライアビリティーカンパニー	マトリクスメタロプロテイナーゼ阻害物質としての４−ヒドロキシキノリン誘導体
GB0220581D0 (en)	2002-09-04	2002-10-09	Novartis Ag	Organic Compound
AU2003276919B2 (en)	2002-09-25	2013-05-16	Memory Pharmaceuticals Corporation	Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
WO2004052348A2 (en)	2002-12-11	2004-06-24	Pharmacia & Upjohn Company Llc	Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
US20050031651A1 (en)	2002-12-24	2005-02-10	Francine Gervais	Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004085433A2 (en)	2003-03-28	2004-10-07	Pharmacia & Upjohn Company Llc	Positive allosteric modulators of the nicotinic acetylcholine receptor
US20050119249A1 (en)	2003-12-02	2005-06-02	Erik Buntinx	Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050245531A1 (en)	2003-12-22	2005-11-03	Abbott Laboratories	Fused bicycloheterocycle substituted quinuclidine derivatives
RU2417225C2 (ru)	2004-03-25	2011-04-27	Мемори Фармасьютиклз Корпорейшн	Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
AU2004325725A1 (en)	2004-12-10	2006-06-22	Abbott Laboratories	Fused bicycloheterocycle substituted quinuclidine derivatives
KR20080048550A (ko)	2005-09-23	2008-06-02	메모리 파마슈티칼스 코포레이션	인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도
ES2555803T3 (es)	2006-10-23	2016-01-08	Cephalon, Inc.	Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
MX2009011830A (es)	2007-05-11	2009-11-13	Pfizer	Compuestos amino-heterociclicos.
ES2529648T3 (es)	2007-08-31	2015-02-24	Eisai R&D Management Co., Ltd.	Compuesto policíclico
US7935815B2 (en)	2007-08-31	2011-05-03	Eisai R&D Management Co., Ltd.	Imidazoyl pyridine compounds and salts thereof
KR101565469B1 (ko)	2007-10-01	2015-11-03	코멘티스, 인코포레이티드	알츠하이머병의 치료를 위한 알파 7 니코틴 아세틸콜린 수용체 리간드로서 퀴누클리딘-4-일메틸 1ｈ-인돌-3-카르복실레이트 유도체
US7902222B2 (en)	2007-11-21	2011-03-08	Abbott Laboratories	Biaryl substituted azabicyclic alkane derivatives
DK2282778T3 (en)	2008-04-29	2017-05-01	Pharnext	NEW THERAPEUTIC APPROACHES TO TREAT ALZHEIMER'S DISEASE AND RELATED DISEASES THROUGH A MODULATION OF ANGIOGENIC
CN102065858B (zh)	2008-04-29	2014-07-02	法奈科斯公司	使用唑尼沙胺和阿坎酸治疗阿尔茨海默病和相关病症的组合组合物
BRPI0911518A2 (pt)	2008-04-29	2017-06-13	Pharnext	novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao estresse de célula
MX2011005096A (es)	2008-11-13	2011-11-18	Link Medicine Corp	Derivados de azaquinolinona y usos de los mismos.
CA2894860C (en)	2008-11-19	2018-11-06	Gerhard Koenig	Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
WO2010071846A2 (en)	2008-12-19	2010-06-24	Afraxis, Inc.	Compounds for treating neuropsychiatric conditions
WO2010075635A1 (en)	2008-12-30	2010-07-08	Ramot At Tel Aviv University Ltd.	Combination therapies using nap
TWI404721B (zh)	2009-01-26	2013-08-11	Pfizer	胺基－雜環化合物
EP2398500B1 (en)	2009-02-20	2019-03-13	2-BBB Medicines B.V.	Glutathione-based drug delivery system
TW201035101A (en)	2009-02-26	2010-10-01	Eisai R&D Man Co Ltd	Nitrogen-containing fused heterocyclic compound
BRPI1013777A8 (pt)	2009-04-13	2017-09-19	Theravance Biopharma R&D Ip Llc	Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos.
SG176628A1 (en)	2009-06-05	2012-01-30	Link Medicine Corp	Aminopyrrolidinone derivatives and uses thereof
WO2011057199A1 (en)	2009-11-06	2011-05-12	Adenios, Inc.	Compositions for treating cns disorders
US20110274628A1 (en)	2010-05-07	2011-11-10	Borschke August J	Nicotine-containing pharmaceutical compositions

2009
- 2009-11-19 CA CA2894860A patent/CA2894860C/en not_active Expired - Fee Related
- 2009-11-19 CN CN201610021941.2A patent/CN105687191A/zh active Pending
- 2009-11-19 MX MX2011005270A patent/MX2011005270A/es active IP Right Grant
- 2009-11-19 PE PE2011001056A patent/PE20110711A1/es not_active Application Discontinuation
- 2009-11-19 PL PL15151165T patent/PL2889033T3/pl unknown
- 2009-11-19 PT PT97569214T patent/PT2355822E/pt unknown
- 2009-11-19 PT PT121859136T patent/PT2540297E/pt unknown
- 2009-11-19 DK DK12185913.6T patent/DK2540297T3/en active
- 2009-11-19 CA CA2744278A patent/CA2744278C/en not_active Expired - Fee Related
- 2009-11-19 RS RS20120560A patent/RS52583B/sr unknown
- 2009-11-19 PT PT151511656T patent/PT2889033T/pt unknown
- 2009-11-19 MY MYPI2011002245A patent/MY159826A/en unknown
- 2009-11-19 EP EP09756921A patent/EP2355822B1/en active Active
- 2009-11-19 ES ES09756921T patent/ES2396300T3/es active Active
- 2009-11-19 TR TR2018/07944T patent/TR201807944T4/tr unknown
- 2009-11-19 CN CN2009801546937A patent/CN102281878A/zh active Pending
- 2009-11-19 EP EP15151165.6A patent/EP2889033B1/en active Active
- 2009-11-19 EP EP18152484.4A patent/EP3357495B1/en active Active
- 2009-11-19 RU RU2011124515/15A patent/RU2532327C2/ru not_active IP Right Cessation
- 2009-11-19 AU AU2009316557A patent/AU2009316557B2/en not_active Ceased
- 2009-11-19 CN CN201610020803.2A patent/CN105687190A/zh active Pending
- 2009-11-19 KR KR1020187002503A patent/KR20180011888A/ko not_active Ceased
- 2009-11-19 CA CA3017886A patent/CA3017886A1/en not_active Abandoned
- 2009-11-19 DK DK15151165.6T patent/DK2889033T3/en active
- 2009-11-19 KR KR1020117013996A patent/KR20110091549A/ko not_active Ceased
- 2009-11-19 EP EP12185913.6A patent/EP2540297B1/en active Active
- 2009-11-19 MY MYPI2014003208A patent/MY173229A/en unknown
- 2009-11-19 NZ NZ613291A patent/NZ613291A/en not_active IP Right Cessation
- 2009-11-19 SG SG10201504102QA patent/SG10201504102QA/en unknown
- 2009-11-19 LT LTEP15151165.6T patent/LT2889033T/lt unknown
- 2009-11-19 ES ES15151165.6T patent/ES2673016T3/es active Active
- 2009-11-19 KR KR1020147032489A patent/KR20140146216A/ko not_active Ceased
- 2009-11-19 JP JP2011537621A patent/JP5272080B2/ja not_active Expired - Fee Related
- 2009-11-19 ES ES12185913.6T patent/ES2541528T3/es active Active
- 2009-11-19 PL PL12185913T patent/PL2540297T3/pl unknown
- 2009-11-19 SI SI200931223T patent/SI2540297T1/sl unknown
- 2009-11-19 HR HRP20130007AT patent/HRP20130007T1/hr unknown
- 2009-11-19 SI SI200931855T patent/SI2889033T1/en unknown
- 2009-11-19 SM SM20180308T patent/SMT201800308T1/it unknown
- 2009-11-19 DK DK09756921.4T patent/DK2355822T3/da active
- 2009-11-19 US US13/129,782 patent/US8642638B2/en not_active Expired - Fee Related
- 2009-11-19 PL PL09756921T patent/PL2355822T3/pl unknown
- 2009-11-19 NZ NZ593467A patent/NZ593467A/xx not_active IP Right Cessation
- 2009-11-19 WO PCT/US2009/065173 patent/WO2010059844A1/en not_active Ceased
- 2009-11-19 SI SI200930466T patent/SI2355822T1/sl unknown
- 2009-11-19 HU HUE15151165A patent/HUE037938T2/hu unknown
- 2009-11-19 HU HUE12185913A patent/HUE026815T2/en unknown
- 2009-11-19 BR BRPI0922057A patent/BRPI0922057A2/pt not_active Application Discontinuation
2011
- 2011-05-16 IL IL212921A patent/IL212921A/en not_active IP Right Cessation
- 2011-05-19 CO CO11061800A patent/CO6400190A2/es not_active Application Discontinuation
- 2011-05-19 CL CL2011001178A patent/CL2011001178A1/es unknown
- 2011-05-20 CR CR20110267A patent/CR20110267A/es unknown
- 2011-05-23 EC EC2011011076A patent/ECSP11011076A/es unknown
- 2011-05-31 ZA ZA2011/04044A patent/ZA201104044B/en unknown
2012
- 2012-11-12 US US13/674,290 patent/US8569354B2/en not_active Expired - Fee Related
2013
- 2013-01-07 CY CY20131100013T patent/CY1113671T1/el unknown
- 2013-01-09 SM SM201300003T patent/SMT201300003B/xx unknown
- 2013-04-17 JP JP2013086454A patent/JP5674854B2/ja not_active Expired - Fee Related
- 2013-12-23 US US14/139,178 patent/US20140148479A1/en not_active Abandoned
2014
- 2014-02-07 US US14/175,654 patent/US8815933B2/en not_active Expired - Fee Related
- 2014-06-04 RU RU2014122858A patent/RU2662560C2/ru not_active IP Right Cessation
- 2014-07-17 PH PH12014501629A patent/PH12014501629B1/en unknown
- 2014-10-08 US US14/509,305 patent/US20150265583A1/en not_active Abandoned
- 2014-11-26 JP JP2014238660A patent/JP5869653B2/ja not_active Expired - Fee Related
2015
- 2015-07-01 HR HRP20150711TT patent/HRP20150711T1/hr unknown
- 2015-07-02 CY CY20151100575T patent/CY1116460T1/el unknown
- 2015-07-10 SM SM201500167T patent/SMT201500167B/xx unknown
- 2015-10-12 IL IL242034A patent/IL242034A/en not_active IP Right Cessation
- 2015-10-12 IL IL242035A patent/IL242035A0/en unknown
2016
- 2016-01-07 JP JP2016001812A patent/JP6223480B2/ja not_active Expired - Fee Related
2017
- 2017-07-18 CL CL2017001853A patent/CL2017001853A1/es unknown
- 2017-10-03 JP JP2017193867A patent/JP2018039818A/ja active Pending
- 2017-10-27 US US15/796,475 patent/US20180271844A1/en not_active Abandoned
- 2017-12-06 IL IL256140A patent/IL256140A/en unknown
- 2017-12-14 IL IL256313A patent/IL256313A/en unknown
2018
- 2018-01-03 PH PH12018500023A patent/PH12018500023A1/en unknown
- 2018-05-25 CL CL2018001420A patent/CL2018001420A1/es unknown
- 2018-06-18 HR HRP20180942TT patent/HRP20180942T1/hr unknown
- 2018-06-20 CY CY20181100638T patent/CY1121607T1/el unknown
- 2018-07-11 RU RU2018125456A patent/RU2018125456A/ru unknown
2019
- 2019-11-22 JP JP2019210985A patent/JP2020040977A/ja active Pending

Also Published As

Publication number	Publication date
HRP20130007T1 (hr)	2013-01-31
SMT201800308T1 (it)	2018-09-13
DK2540297T3 (en)	2015-07-13
EP3357495A1 (en)	2018-08-08
IL242034A0 (en)	2015-11-30
DK2355822T3 (da)	2013-01-28
CL2017001853A1 (es)	2018-05-11
JP2013166771A (ja)	2013-08-29
JP6223480B2 (ja)	2017-11-01
EP2889033B1 (en)	2018-03-21
PH12018500023A1 (en)	2019-07-15
PH12014501629A1 (en)	2016-01-18
CA2894860C (en)	2018-11-06
EP2540297B1 (en)	2015-04-08
NZ613291A (en)	2014-11-28
CY1116460T1 (el)	2017-03-15
SMT201300003B (it)	2013-05-06
JP2015083574A (ja)	2015-04-30
HUE037938T2 (hu)	2018-09-28
SI2889033T1 (en)	2018-08-31
CA3017886A1 (en)	2010-05-27
RU2014122858A (ru)	2015-12-10
WO2010059844A1 (en)	2010-05-27
CR20110267A (es)	2011-10-13
NZ593467A (en)	2013-07-26
PT2355822E (pt)	2013-01-14
MY159826A (en)	2017-02-15
US20140155430A1 (en)	2014-06-05
CN102281878A (zh)	2011-12-14
EP2540297A1 (en)	2013-01-02
PL2355822T3 (pl)	2013-03-29
US20130137717A1 (en)	2013-05-30
CL2011001178A1 (es)	2011-10-14
RS52583B (sr)	2013-04-30
US8815933B2 (en)	2014-08-26
US20180271844A1 (en)	2018-09-27
EP2889033A1 (en)	2015-07-01
HUE026815T2 (en)	2016-07-28
MX2011005270A (es)	2011-08-03
KR20140146216A (ko)	2014-12-24
US20140148479A1 (en)	2014-05-29
JP5272080B2 (ja)	2013-08-28
US8569354B2 (en)	2013-10-29
CN105687191A (zh)	2016-06-22
KR20110091549A (ko)	2011-08-11
SI2355822T1 (sl)	2013-02-28
RU2662560C2 (ru)	2018-07-26
PL2540297T3 (pl)	2015-12-31
CN105687190A (zh)	2016-06-22
PH12014501629B1 (en)	2016-01-18
AU2009316557B2 (en)	2015-08-27
PT2889033T (pt)	2018-06-18
JP5869653B2 (ja)	2016-02-24
RU2532327C2 (ru)	2014-11-10
PE20110711A1 (es)	2011-10-11
PT2540297E (pt)	2015-08-26
IL212921A (en)	2015-11-30
ECSP11011076A (es)	2011-09-30
IL212921A0 (en)	2011-07-31
IL256140A (en)	2018-02-28
JP2020040977A (ja)	2020-03-19
CA2894860A1 (en)	2010-05-27
AU2009316557A1 (en)	2010-05-27
ES2396300T3 (es)	2013-02-20
TR201807944T4 (tr)	2018-06-21
IL242035A0 (en)	2015-11-30
DK2889033T3 (en)	2018-07-02
CY1113671T1 (el)	2016-07-27
IL256313A (en)	2018-02-28
JP2012509347A (ja)	2012-04-19
SI2540297T1 (sl)	2015-08-31
JP2016128442A (ja)	2016-07-14
IL242034A (en)	2017-12-31
CO6400190A2 (es)	2012-03-15
PL2889033T3 (pl)	2018-10-31
SMT201500167B (it)	2015-09-07
ZA201104044B (en)	2012-11-28
SG10201504102QA (en)	2015-06-29
ES2541528T3 (es)	2015-07-21
JP2018039818A (ja)	2018-03-15
ES2673016T3 (es)	2018-06-19
MY173229A (en)	2020-01-07
KR20180011888A (ko)	2018-02-02
RU2018125456A (ru)	2020-01-13
CY1121607T1 (el)	2020-05-29
HRP20150711T1 (hr)	2015-08-14
EP3357495B1 (en)	2019-12-25
HRP20180942T1 (hr)	2018-08-10
RU2011124515A (ru)	2012-12-27
US20150265583A1 (en)	2015-09-24
US20110288119A1 (en)	2011-11-24
JP5674854B2 (ja)	2015-02-25
HK1158520A1 (en)	2012-07-20
CL2018001420A1 (es)	2018-09-28
US8642638B2 (en)	2014-02-04
CA2744278A1 (en)	2010-05-27
EP2355822B1 (en)	2012-10-10
EP2355822A1 (en)	2011-08-17
BRPI0922057A2 (pt)	2015-12-15
CA2744278C (en)	2015-09-08

Publication	Publication Date	Title
HUE037938T2 (hu)	2018-09-28	Skizofrénia negatív tüneteinek kezelése (R)-7-klór-N-(kinuklidin-3-il)benzo[b]tiofén-2-karboxamiddal és ennek gyógyszerészetileg elfogadható sójával
NZ603625A (en)	2014-10-31	A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
AP3069A (en)	2014-12-31	Thienopyridine derivatives for the treatment and prvention of dengue virus infection
IL211279A (en)	2015-03-31	Use of the tspan12 antagonist in the preparation of a blood vessel inhibition drug
HUP0700369A2 (en)	2009-04-28	Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
HUP0700370A2 (en)	2009-04-28	Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
EP2121729A4 (en)	2013-07-31	PHARMACEUTICAL, SUBSTANTIVE SALTS OF THYMODEPRESSINE AND METHOD FOR THE PRODUCTION THEREOF
ZA200900556B (en)	2009-12-30	Use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders